Lysergic Acid Diethylamide (LSD) Rapid Test

An LSD Rapid Test is a drug abuse screening device used to detect LSD-related exposure in a urine specimen. It is commonly used as a first-level screening tool where fast, practical, and easy-to-read results are required. Urine testing is widely used in drug screening because it is non-invasive, simple to collect, and suitable for routine professional testing programs.

• LSD is classified as a hallucinogen. Hallucinogens can cause experiences that appear real but are created by the mind, and LSD is known for strong perception-altering effects.
• For organizations and healthcare-related screening programs, an LSD urine test helps support workplace drug abuse screening, clinical toxicology screening, rehabilitation monitoring, forensic testing, institutional testing, public safety programs, and international diagnostic distribution needs.
• The LARKSOIS Pharma LSD Rapid Test provides a practical solution for preliminary urine-based screening in environments where fast decision support is required.

The 50ng/ml cut-off means the Lysergic Acid Diethylamide (LSD) Rapid Test is designed to screen urine specimens at this threshold. If LSD concentration in the urine specimen meets or exceeds the cut-off level, the test may show a presumptive positive result. If the concentration is below the cut-off, the test may show a negative result. Cut-off values help standardize interpretation, but rapid screening results may be influenced by specimen quality, collection time, individual metabolism, storage conditions, test handling, and result reading time.

• The LSD Rapid Test by LARKSOIS Pharma is designed for simple professional testing. A urine specimen is collected, applied to the test device according to the product insert, and results are interpreted within the recommended reading time.
• The result should always be checked with the control indicator to confirm that the test has run correctly.
• The test provides a qualitative result, meaning it indicates whether LSD is detected above or below the specified product cut-off.

Instructions

• A valid control indicator must appear
• A positive result is presumptive only
• A negative result does not always rule out exposure
• Results should be read only within the recommended time window
• Non-negative results should be confirmed by a certified laboratory method
• Testing should follow local laws, workplace policies, and professional protocols

Instructions

• Urine-based LSD drug abuse screening
• 50ng/ml cut-off level
• Rapid test method for preliminary detection
• Suitable for professional testing programs
• Simple visual result interpretation
• Useful for workplace, clinical, forensic, and rehabilitation settings
• Supports targeted and expanded drug screening panels
• Suitable for international diagnostic supply
• Designed for practical screening workflows
• Supplied by LARKSOIS Pharma for global markets

The Lysergic Acid Diethylamide (LSD) Rapid Test by LARKSOIS Pharma can be used across multiple professional settings where preliminary LSD screening support is required.

Applications

• Workplace drug abuse screening
• Clinical toxicology screening
• Rehabilitation and recovery monitoring
• Forensic and legal screening workflows
• Institutional and correctional facility testing
• Public safety and compliance programs
• International diagnostic distribution
• Laboratory and professional screening workflows

The Lysergic Acid Diethylamide (LSD) Rapid Test works on an immunoassay-based principle. When the urine specimen is applied to the test device, it reacts with specific reagents designed for LSD screening.

Benefits

• Urine-based rapid screening format
• 50ng/ml LSD cut-off
• Designed for LSD drug screening
• Suitable for professional diagnostic use
• Supports fast preliminary results
• Useful for workplace, forensic, clinical, rehabilitation, and institutional workflows
• Applicable for laboratories, hospitals, diagnostic centers, and distributors
• Supports international drug screening requirements

The LSD Rapid Test is designed for urine specimens. Urine testing is widely used in drug screening because it is non-invasive, simple to collect, and suitable for routine professional testing programs.

Guidance

• Use urine specimen only
• Follow the product insert carefully
• Use clean sample collection procedures
• Treat all urine specimens as potentially biohazardous
• Read results only within the recommended time window
• Use confirmatory testing where required by clinical, legal, workplace, forensic, or institutional policy

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

• The LSD rapid urine test plays an important role in drug-of-abuse screening because LSD misuse can create health, safety, workplace, and legal concerns.
• In professional testing programs, rapid screening helps identify samples that may require further laboratory evaluation.
• For global buyers, the LSD Rapid Test 50ng/ml is a useful product for diagnostic portfolios, drug testing panels, rehabilitation support, workplace safety programs, forensic screening, and institutional monitoring applications.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Lysergic Acid Diethylamide (LSD) Rapid Test.

Positive

A positive or non-negative result suggests that LSD may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method where required.

Negative

A negative result suggests that LSD was not detected or was below the cut-off at the time of testing. A negative result does not always rule out exposure if sample quality, collection timing, or the detection window affects the result.

Invalid

If the valid control indicator does not appear, the test is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store in a cool and dry place
• Keep away from direct sunlight and moisture
• Do not freeze the test device
• Keep the pouch sealed until use
• Do not use damaged or opened packaging
• Do not use after the expiry date
• Follow the storage temperature mentioned on the product label

Note

Proper storage helps protect the reliability of the LSD urine rapid test and ensures consistent screening performance.

Instructions

• For professional in-vitro screening use only
• Use urine specimen only as directed
• Do not reuse the test device
• Follow the product insert carefully
• Wear gloves and follow standard hygiene practices
• Handle all urine specimens as potentially infectious material
• Avoid using expired or damaged test kits
• Do not interpret results after the recommended reading time
• Confirm presumptive positive results with laboratory testing
• Follow applicable drug testing laws and reporting requirements

LARKSOIS Pharma provides professional diagnostic and pharmaceutical solutions for international healthcare and screening markets. The Lysergic Acid Diethylamide (LSD) Rapid Test is developed for buyers who require a practical, reliable, and globally suitable drug abuse screening product.

Advantages

• International-quality product approach
• Professional drug of abuse rapid test portfolio
• Suitable for bulk and institutional supply
• Practical urine-based screening format
• Distributor-friendly product range
• Focus on consistency, usability, and screening reliability
• Suitable for workplace, forensic, clinical, and rehabilitation markets